Green tea therapy can significantly improve rheumatoid arthritis symptoms, correlating with changes in specific circulating serum molecules, miR-125b and miR-146a.
In this study, 100 female patients suffering from rheumatoid arthritis and 50 healthy female subjects were examined. Patients with rheumatoid arthritis underwent green tea therapy, where they consumed 5 cups of green tea daily, delivering a total of 1230 mg of catechins, over a span of 24 weeks. During this time, researchers used real-time PCR analysis to measure the levels of miR-146a and miR-125 b in the patients' peripheral blood mononuclear cells. These cells were isolated from the subjects at three distinct stages: the starting point (baseline), after 12 weeks, and finally after 24 weeks of the treatment.
The observations revealed a notable increase in the level of circulating miR-125 b and decrease in miR-146 expression, and these shifts were seen to correspond positively with measures of disease activity and pain intensity in the patients after 24 weeks of the green tea therapy. Also of note was that the levels of miR-146a and miR-125b could accurately predict the clinical response to green tea therapy in 65% of the rheumatoid arthritis patients. Discrepancies in miR-146a and miR-125b levels following green tea therapy suggests that they may be attributed to the joint protective, antioxidant, and anti-inflammatory effects of green tea. It was therefore proposed that both miR-146a and miR-125b could potentially serve as diagnostic, therapeutic, and predictive biomarkers in green tea therapy and may even have valuable application in related non-drug rheumatoid arthritis therapy.
